Physician profile
William Weigold
NPI 1326085531
$3,922.77
in general payments reported to CMS, 2019-2025
30 companies · $883 in 2025
The $883 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.31 · 2022: $740 · 2023: $1,067 · 2024: $1,153 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,103.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $593.88 | 2021-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $470.75 | 2021-2025 | |
| Pfizer INC. | $336.40 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $306.04 | 2022-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $228.38 | 2023-2025 | Opsumit, Opsynvi, Uptravi |
| Astrazeneca Pharmaceuticals LP | $209.09 | 2022-2025 | Farxiga, Brilinta |
| Amgen INC. | $189.46 | 2022-2025 | Repatha, Repatha |
| Philips North America LLC | $181.72 | 2022-2025 | (Ck4) Mcot, Ecc Solutions, (Ck7) Extended Holter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $173.82 | 2022-2025 | Lifevest |
| Novo Nordisk INC | $147.79 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $136.50 | 2022-2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $135.04 | 2022-2025 | Amvuttra |
| Boston Scientific Corporation | $99.03 | 2024 | Watchman, Bodyguardian |
| Kiniksa Pharmaceuticals, LTD. | $93.71 | 2023 | Arcalyst |
| Atricure, INC. | $91.57 | 2022-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $73.99 | 2021-2024 | |
| Medicomp INC | $68.38 | 2024-2025 | Telepatch Cardiac Monitor |
| Esperion Therapeutics, INC. | $53.27 | 2022-2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $53.05 | 2024 | Arcalyst |
| Baxter Healthcare | $45.38 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Irhythm Technologies, INC. | $32.92 | 2024 | Zio Monitor, Zio Xt Patch |
| Bridgebio Pharma, INC. | $30.75 | 2025 | Attruby |
| Daiichi Sankyo INC. | $27.39 | 2025 | Injectafer |
| Inspire Medical Systems, INC. | $25.11 | 2025 | Inspire |
| Lexicon Pharmaceuticals, INC. | $24.43 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.25 | 2022 | |
| Celgene Corporation | $22.72 | 2025 | Camzyos |
| Vital Connect, INC | $20.95 | 2023 | Vitalpatch Rtm |
| Stryker Corporation | $15.01 | 2021 | |
| Amarin Pharma, INC. | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Weigold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.